MENLO PARK, Calif.,
Jan. 11, 2021 /PRNewswire/ -- The
Foundry today announced the successful completion of the
first-in-human procedure with the Half Moon Medical transcatheter
mitral repair technology (TMVr) at Oregon Health and Science
University (OHSU) as part of an FDA-approved early feasibility
study. The first patient treated has been discharged from the
hospital and is recovering as expected.
The investigational Half Moon mitral valve repair device,
developed through a unique partnership between Medtronic (NYSE:MDT)
and The Foundry, is designed to restore function in a diseased
mitral valve in patients with severe symptomatic mitral
regurgitation (MR), a disease where blood leaks backwards within
the heart due to the mitral valve's inability to close
properly.
"We are pleased to be able to offer our patients new options for
heart valve repair as early as possible through studies such as
this," said Firas Zahr, M.D., OHSU
interventional cardiology director, who co-led the procedure.
"Minimally invasive transcatheter heart valve repair can offer
relief from mitral valve regurgitation without the need for
traditional open-heart surgery," said Howard Song, M.D., Ph.D., OHSU cardiothoracic
surgery division chief, who co-led the procedure. Scott Chadderdon, M.D., OHSU Knight
Cardiovascular Institute clinical trials director, also led
echocardiography to guide the procedure.
The Half Moon mitral valve repair device is unique from other
mitral valve repair technologies in maintaining more natural
physiologic functionality of the mitral valve. It is deployed using
a transfemoral (through the leg) delivery catheter, which is
navigated through the vasculature to the diseased native mitral
valve. The device is fully repositionable and recoverable during
deployment and preserves options for patients who may need
re-intervention in the future.
"This technology is a truly innovative solution designed to
eliminate regurgitation by restoring physiologic coaptation of the
native mitral valve," said Matt
McLean, Co-Founder and Chief Operating Officer at Half Moon
Medical, the sixteenth Foundry company, founded in 2017. "On behalf
of the entire team at Half Moon, I would like to congratulate the
team at OHSU on this incredible achievement."
Mitral regurgitation is the most common heart valve disease in
the US, affecting an estimated four million people. If left
untreated, MR may lead to chronic heart failure, the leading cause
of hospitalization in the U.S. and Europe.
About The Foundry
The Foundry was founded in 1998 to
rapidly translate concepts into successful new medical device
companies. In addition to inventing new technologies itself, The
Foundry works closely with outside inventors with promising ideas.
Over the past 22 years, The Foundry has formed over 22 new
companies, including Evalve (Abbott- MitraClip) and Twelve
(Medtronic- Intrepid) in the structural heart space. Other
companies include Concentric Medical (acquired by Stryker),
Emphasys (acquired by Pulmonx), Ardian (acquired by Medtronic), and
incubator Forsight Labs, which has created several successful
ophthalmic companies. The Foundry, LLC is located in Menlo Park, California. For more information,
visit the company's website at www.thefoundry.com.
Contacts:
Katy Frame
(610)-613-3549
kframe@brgcommunications.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/the-foundry-announces-successful-first-in-human-procedure-in-study-of-innovative-transcatheter-mitral-valve-repair-technology-301204824.html
SOURCE The Foundry